Tiziana Life Sciences Ltd./$TLSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Ticker
$TLSA
Sector
Primary listing
Employees
10
Headquarters
Website
TLSA Metrics
BasicAdvanced
$140m
-
-$0.16
0.40
-
Price and volume
Market cap
$140m
Beta
0.4
52-week high
$2.60
52-week low
$1.04
Average daily volume
255k
Financial strength
Current ratio
0.763
Quick ratio
0.722
Long term debt to equity
450
Total debt to equity
876.923
Interest coverage (TTM)
-1,174.00%
Profitability
EBITDA (TTM)
-21.12
Management effectiveness
Return on assets (TTM)
-115.96%
Return on equity (TTM)
-924.32%
Valuation
Price to book
2,505.8
Price to tangible book (TTM)
2,505.8
Price to free cash flow (TTM)
-9.927
Free cash flow yield (TTM)
-10.07%
Free cash flow per share (TTM)
-0.109
Growth
Earnings per share change (TTM)
40.12%
3-year earnings per share growth (CAGR)
0.91%
10-year earnings per share growth (CAGR)
2.04%
TLSA News
AllArticlesVideos
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Proactive Investors·4 weeks ago
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Proactive Investors·4 weeks ago
Tiziana Life Sciences price target boosted on foralumab update
Proactive Investors·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs